Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/nanopublications.trig#NP751783.RAeNeXwYhl6pDmBg_4N3JCmJ2O5AJwfZsXlLT77tIR6FM130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP751783.RAeNeXwYhl6pDmBg_4N3JCmJ2O5AJwfZsXlLT77tIR6FM130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP751783.RAeNeXwYhl6pDmBg_4N3JCmJ2O5AJwfZsXlLT77tIR6FM130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP751783.RAeNeXwYhl6pDmBg_4N3JCmJ2O5AJwfZsXlLT77tIR6FM130_provenance.
- NP751783.RAeNeXwYhl6pDmBg_4N3JCmJ2O5AJwfZsXlLT77tIR6FM130_assertion description "[Topoisomerase II (TOP2) targeting drugs like doxorubicin and etoposide are frontline chemotherapeutics for a wide variety of solid and hematological malignancies, including breast and ovarian adenocarcinomas, lung cancers, soft tissue sarcomas, leukemias and lymphomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP751783.RAeNeXwYhl6pDmBg_4N3JCmJ2O5AJwfZsXlLT77tIR6FM130_provenance.
- NP751783.RAeNeXwYhl6pDmBg_4N3JCmJ2O5AJwfZsXlLT77tIR6FM130_assertion evidence source_evidence_literature NP751783.RAeNeXwYhl6pDmBg_4N3JCmJ2O5AJwfZsXlLT77tIR6FM130_provenance.
- NP751783.RAeNeXwYhl6pDmBg_4N3JCmJ2O5AJwfZsXlLT77tIR6FM130_assertion SIO_000772 22900064 NP751783.RAeNeXwYhl6pDmBg_4N3JCmJ2O5AJwfZsXlLT77tIR6FM130_provenance.
- NP751783.RAeNeXwYhl6pDmBg_4N3JCmJ2O5AJwfZsXlLT77tIR6FM130_assertion wasDerivedFrom befree-20140225 NP751783.RAeNeXwYhl6pDmBg_4N3JCmJ2O5AJwfZsXlLT77tIR6FM130_provenance.
- NP751783.RAeNeXwYhl6pDmBg_4N3JCmJ2O5AJwfZsXlLT77tIR6FM130_assertion wasGeneratedBy ECO_0000203 NP751783.RAeNeXwYhl6pDmBg_4N3JCmJ2O5AJwfZsXlLT77tIR6FM130_provenance.
- befree-20140225 importedOn "2014-02-25" NP751783.RAeNeXwYhl6pDmBg_4N3JCmJ2O5AJwfZsXlLT77tIR6FM130_provenance.